Stem Cell technology breakthroughs continue to ramp up the space.
RGS is funded for the next 2 years. IPO was at 25 cents, oversubscribed, with about 70m shares listed.
Impressive list of biotech directors and management.
Has had some very impressive breakthroughs with animal models (as the video from channel 9's report shows).
Hopefully, these successes can be repeated in human trials, if so, the potential for generating profits from stem cell injections for arthritis is enormous.
If you are a biotech investor, and especially if you are interested in stem cell technology (ie. MSB, ECQ, AHZ etc), then put this on your watch list and do some research.
Gw
RGS Price at posting:
27.5¢ Sentiment: LT Buy Disclosure: Held